Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | KDR Q472H |
Therapy | Dabrafenib + Lenvatinib |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KDR Q472H | melanoma | sensitive | Dabrafenib + Lenvatinib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with the combination of Tafinlar (dabrafenib) and Lenvima (lenvatinib) synergistically inhibited viability of melanoma cell lines expressing KDR Q472H compared to cells expressing wild-type KDR in culture (PMID: 38201446). | 38201446 |
PubMed Id | Reference Title | Details |
---|---|---|
(38201446) | Kinase Insert Domain Receptor Q472H Pathogenic Germline Variant Impacts Melanoma Tumor Growth and Patient Treatment Outcomes. | Full reference... |